uniQure N.V.

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026

Company Profile

IndustryBiotechnology

SectorHealthcare

ExchangeNASDAQ

Market Capitalization1,555.89 mln

Float64.46 mln

Earnings Date11/10/2026

Piotroski F-Score

5 / 9

Neutral

Beneish M-Score

-4.45

Highly reliable

1-Year Forecast

60.37

Transformational upside

Relative Strength

57 / 100

Slightly ahead

Debt / Equity

1.70

High leverage

Pre-Tax Margin

-1,313%

Severely loss-making

Business Description

uniQure N.V. is a Dutch biotech company founded in 1998 that creates gene therapies for people living with serious rare diseases. Its approved product, HEMGENIX, helps hemophilia B patients produce a protein that reduces dangerous bleeding episodes. The company has several treatments in clinical trials targeting conditions such as Huntington's disease, epilepsy, ALS, and Fabry disease. uniQure operates from its headquarters in Amsterdam and holds key partnerships to support the development and supply of its therapies.

Key Fundamentals

EPS-4.03

ROE-141

RPS0.30

ROIC-90.64

ROA-31.05

Interest Cover-3.41

EBITDA, mln-171

EV / EBITDA-7.46

EV / EBIT-6.88

Revenue, mln18.67

EV / Revenue68.30

Quote Details

Last 22.43

Change -0.68 (-2.94%)

Open 23.11

Volume 880,995

Turnover 19,760,718

Average Volume 3,363,361

Financial Ratios

Pre-Tax Profit Margin-1,313

Leverage Ratio3.04

Current Ratio10.01

Price / Book5.17

Price / Tangible Book7.06

Debt / Equity1.70

Price / Sales81.33

Financial Strength

Altman Z-Score-0.22

Piotroski F-Score 5 / 9

Beneish M-Score-4.45

1-Year Target Price60.37

Short Ratio2.90

Short % of Float12.73

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	2.98%	83 / 100
1 Month	-41.47%	6 / 100
2 Months	-43.5%	10 / 100
6 Months	24.4%	91 / 100
1 Year	-62.56%	14 / 100